Ann Rheum Dis: Severe new crown pneumonia inflammatory storm sarilumab uses sarilumab to block the efficacy of interleukin-6.

The study was designed to assess the safety and efficacy of using blocking interleukin in patients with severe neo-coronary pneumonia associated with systemic inflammatory stormsAn open label study was conducted on patients with severe new coronary pneumonia associated with an over-inflammatory response (an increase in inflammatory markers and serum levels)In addition to standard treatment, additional intravenous injections are provided and the results are compared to matching patients who receive only standard treatmentAssess clinical improvement, mortality, safety, and reaction predictors on the first dayPatients who received treatment were only treated with standard treatment and were used as a control groupOn the first day of follow-up, % of the treated patients had clinical improvement and % of the patients diedThese findings showed no significant difference from the control group (clinical improvement rate % mortality % ;)The baseline ratio and the scanned pulmonary reality% can predict clinical improvement in the treatment of patientsPatients with pulmonary reality % used a median time (days) of treatment that achieved clinical improvement shorter than the standard treatment (days;)The infection rates were similar to those of the two groupsThere was no significant difference between the overall clinical improvement rate and mortality rate of patients with severe new coronary pneumonia and standard treatmentIn the subgroup of patients with mild baseline pulmonary reality was associated with faster recovery